ABUS Stock Overview
A biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Arbutus Biopharma Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.10 |
52 Week High | US$3.64 |
52 Week Low | US$1.69 |
Beta | 1.97 |
11 Month Change | -7.46% |
3 Month Change | 20.16% |
1 Year Change | 38.39% |
33 Year Change | -0.96% |
5 Year Change | 43.52% |
Change since IPO | -55.97% |
Recent News & Updates
Recent updates
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12Shareholder Returns
ABUS | US Biotechs | US Market | |
---|---|---|---|
7D | 5.1% | -0.3% | 0.3% |
1Y | 38.4% | 11.0% | 22.5% |
Return vs Industry: ABUS exceeded the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: ABUS exceeded the US Market which returned 22.9% over the past year.
Price Volatility
ABUS volatility | |
---|---|
ABUS Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ABUS has not had significant price volatility in the past 3 months.
Volatility Over Time: ABUS's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 73 | Mike McElhaugh | www.arbutusbio.com |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Arbutus Biopharma Corporation Fundamentals Summary
ABUS fundamental statistics | |
---|---|
Market cap | US$568.04m |
Earnings (TTM) | -US$74.38m |
Revenue (TTM) | US$12.99m |
45.1x
P/S Ratio-7.9x
P/E RatioIs ABUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABUS income statement (TTM) | |
---|---|
Revenue | US$12.99m |
Cost of Revenue | US$70.83m |
Gross Profit | -US$57.84m |
Other Expenses | US$16.54m |
Earnings | -US$74.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.39 |
Gross Margin | -445.42% |
Net Profit Margin | -572.81% |
Debt/Equity Ratio | 5.6% |
How did ABUS perform over the long term?
See historical performance and comparison